XII Medical, a California-based medical device firm, has closed a series B equity financing round worth $45 million to advance its neuromodulation therapy platform for obstructive sleep apnea (OSA).
The therapy, which alters pain signaling in the body to improve function, aims to enhance the quality of life of patients with OSA, according to the firm.
